TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis, Uveitis
About this trial
This is an interventional treatment trial for Juvenile Rheumatoid Arthritis focused on measuring Ocular Inflammation, Children, Immunotherapy, Cytokine, Clinical Trial, Uveitis, Immunosuppression, Joint, Inflammation
Eligibility Criteria
INCLUSION CRITERIA: Meet American College of Rheumatology Criteria for JRA. Have active anterior uveitis defined as the presence of inflammatory cells (Grade 1+ or higher) in the anterior chamber of at least one eye or the current use of topical corticosteroids to control exacerbation of disease at a frequency of TID or higher. Be between 2 and 18 years, inclusive. Be able to undergo slit lamp biomicroscopy for assessment of anterior chamber cells. Be able to comply with study requirements. Be up to date on all recommended childhood immunizations. Have been using current arthritis regimen for at least 8 weeks prior to enrollment. EXCLUSION CRITERIA: Have a media opacity that precludes assessment of anterior chamber inflammation. Have a periocular injection of corticosteroids within 2 months of baseline, or used a systemic experimental therapy within one month of baseline evaluation. Be currently receiving disease modifying antirheumatic therapy (DMARD), with the exception of prednisone at a dose no greater than 1.0 mg/kg/day, or methotrexate at a dose no greater than 15 mg/m(2)/week. Have active eye or joint inflammation requiring immediate addition or increase in systemic anti-inflammatory medications. Be a Female who is pregnant or lactating . Refuse to use contraception during the study and 6 months after termination of active study therapy, if child-bearing or fathering potential exists. Have used Latanoprost within two weeks prior to enrollment, or have a current or likely need for Latanoprost during the course of the study. Have hypersensitivity to fluorescein dye. Have active serious infections or history of recurring serious infections. Evidence of spondyloarthropathy or entheseopathy.
Sites / Locations
- National Eye Institute (NEI)